false2020Q30001637761December 31P3YP1Y12000016377612020-01-012020-09-30xbrli:shares00016377612020-11-04iso4217:USD00016377612020-07-012020-09-3000016377612019-07-012019-09-3000016377612019-01-012019-09-30iso4217:USDxbrli:shares00016377612020-09-3000016377612019-12-3100016377612018-12-3100016377612019-09-300001637761us-gaap:CommonStockMember2019-12-310001637761us-gaap:AdditionalPaidInCapitalMember2019-12-310001637761us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-12-310001637761us-gaap:RetainedEarningsMember2019-12-310001637761us-gaap:RetainedEarningsMember2020-01-012020-03-3100016377612020-01-012020-03-310001637761us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-01-012020-03-310001637761us-gaap:CommonStockMember2020-01-012020-03-310001637761us-gaap:AdditionalPaidInCapitalMember2020-01-012020-03-310001637761us-gaap:CommonStockMember2020-03-310001637761us-gaap:AdditionalPaidInCapitalMember2020-03-310001637761us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-03-310001637761us-gaap:RetainedEarningsMember2020-03-3100016377612020-03-310001637761us-gaap:RetainedEarningsMember2020-04-012020-06-3000016377612020-04-012020-06-300001637761us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-04-012020-06-300001637761us-gaap:CommonStockMember2020-04-012020-06-300001637761us-gaap:AdditionalPaidInCapitalMember2020-04-012020-06-300001637761us-gaap:CommonStockMember2020-06-300001637761us-gaap:AdditionalPaidInCapitalMember2020-06-300001637761us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-06-300001637761us-gaap:RetainedEarningsMember2020-06-3000016377612020-06-300001637761us-gaap:RetainedEarningsMember2020-07-012020-09-300001637761us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-07-012020-09-300001637761us-gaap:CommonStockMember2020-07-012020-09-300001637761us-gaap:AdditionalPaidInCapitalMember2020-07-012020-09-300001637761us-gaap:CommonStockMember2020-09-300001637761us-gaap:AdditionalPaidInCapitalMember2020-09-300001637761us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-09-300001637761us-gaap:RetainedEarningsMember2020-09-300001637761us-gaap:CommonStockMember2018-12-310001637761us-gaap:AdditionalPaidInCapitalMember2018-12-310001637761us-gaap:AccumulatedOtherComprehensiveIncomeMember2018-12-310001637761us-gaap:RetainedEarningsMember2018-12-310001637761us-gaap:RetainedEarningsMember2019-01-012019-03-3100016377612019-01-012019-03-310001637761us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-01-012019-03-310001637761us-gaap:CommonStockMember2019-01-012019-03-310001637761us-gaap:AdditionalPaidInCapitalMember2019-01-012019-03-310001637761us-gaap:CommonStockMember2019-03-310001637761us-gaap:AdditionalPaidInCapitalMember2019-03-310001637761us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-03-310001637761us-gaap:RetainedEarningsMember2019-03-3100016377612019-03-310001637761us-gaap:RetainedEarningsMember2019-04-012019-06-3000016377612019-04-012019-06-300001637761us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-04-012019-06-300001637761us-gaap:CommonStockMember2019-04-012019-06-300001637761us-gaap:AdditionalPaidInCapitalMember2019-04-012019-06-300001637761us-gaap:CommonStockMember2019-06-300001637761us-gaap:AdditionalPaidInCapitalMember2019-06-300001637761us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-06-300001637761us-gaap:RetainedEarningsMember2019-06-3000016377612019-06-300001637761us-gaap:RetainedEarningsMember2019-07-012019-09-300001637761us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-07-012019-09-300001637761us-gaap:CommonStockMember2019-07-012019-09-300001637761us-gaap:AdditionalPaidInCapitalMember2019-07-012019-09-300001637761us-gaap:CommonStockMember2019-09-300001637761us-gaap:AdditionalPaidInCapitalMember2019-09-300001637761us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-09-300001637761us-gaap:RetainedEarningsMember2019-09-30xbrli:pure0001637761us-gaap:SupplierConcentrationRiskMember2020-01-012020-09-300001637761spne:CreditAgreementMember2015-12-242015-12-240001637761us-gaap:RevolvingCreditFacilityMemberspne:CreditAgreementMember2015-12-240001637761us-gaap:RevolvingCreditFacilityMemberspne:CreditAgreementMember2020-09-300001637761spne:CreditAgreementMember2015-12-240001637761spne:CreditAgreementMembersrt:MaximumMember2015-12-240001637761us-gaap:BaseRateMemberspne:CreditAgreementContingentInterestRateOneMember2015-12-242015-12-240001637761spne:CreditAgreementContingentInterestRateOneMemberus-gaap:LondonInterbankOfferedRateLIBORMember2015-12-242015-12-240001637761spne:CreditAgreementMembersrt:MinimumMember2015-12-240001637761us-gaap:BaseRateMemberspne:CreditAgreement.ContingentInterestRateTwoMember2015-12-242015-12-240001637761spne:CreditAgreement.ContingentInterestRateTwoMemberus-gaap:LondonInterbankOfferedRateLIBORMember2015-12-242015-12-240001637761spne:CreditAgreementContingentInterestRateThreeMemberus-gaap:BaseRateMember2015-12-242015-12-240001637761spne:CreditAgreementContingentInterestRateThreeMemberus-gaap:LondonInterbankOfferedRateLIBORMember2015-12-242015-12-240001637761spne:CreditAgreementMembersrt:MinimumMember2015-12-242015-12-240001637761spne:CreditAgreementMembersrt:MaximumMember2015-12-242015-12-240001637761us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2020-09-300001637761us-gaap:LeaseholdImprovementsMember2020-09-300001637761us-gaap:LeaseholdImprovementsMember2019-12-310001637761us-gaap:EquipmentMember2020-09-300001637761us-gaap:EquipmentMember2019-12-310001637761srt:MinimumMemberus-gaap:EquipmentMember2020-01-012020-09-300001637761srt:MaximumMemberus-gaap:EquipmentMember2020-01-012020-09-300001637761spne:InstrumentSetsMember2020-09-300001637761spne:InstrumentSetsMember2019-12-310001637761srt:MinimumMemberspne:InstrumentSetsMember2020-01-012020-09-300001637761srt:MaximumMemberspne:InstrumentSetsMember2020-01-012020-09-300001637761spne:SoftwareandComputerEquipmentMember2020-09-300001637761spne:SoftwareandComputerEquipmentMember2019-12-310001637761srt:MinimumMemberspne:SoftwareandComputerEquipmentMember2020-01-012020-09-300001637761srt:MaximumMemberspne:SoftwareandComputerEquipmentMember2020-01-012020-09-300001637761us-gaap:FurnitureAndFixturesMember2020-09-300001637761us-gaap:FurnitureAndFixturesMember2019-12-310001637761srt:MinimumMemberus-gaap:FurnitureAndFixturesMember2020-01-012020-09-300001637761srt:MaximumMemberus-gaap:FurnitureAndFixturesMember2020-01-012020-09-300001637761us-gaap:ConstructionInProgressMember2020-09-300001637761us-gaap:ConstructionInProgressMember2019-12-310001637761us-gaap:LeaseholdImprovementsMembersrt:MinimumMember2020-01-012020-09-300001637761us-gaap:LeaseholdImprovementsMembersrt:MaximumMember2020-01-012020-09-300001637761us-gaap:TechnologyBasedIntangibleAssetsMember2020-01-012020-09-300001637761us-gaap:TechnologyBasedIntangibleAssetsMember2020-09-300001637761us-gaap:CustomerRelationshipsMember2020-01-012020-09-300001637761us-gaap:CustomerRelationshipsMember2020-09-300001637761us-gaap:TrademarksAndTradeNamesMember2020-09-300001637761us-gaap:TechnologyBasedIntangibleAssetsMember2019-01-012019-12-310001637761us-gaap:TechnologyBasedIntangibleAssetsMember2019-12-310001637761us-gaap:CustomerRelationshipsMember2019-01-012019-12-310001637761us-gaap:CustomerRelationshipsMember2019-12-310001637761us-gaap:TrademarksAndTradeNamesMember2019-12-310001637761us-gaap:CostOfSalesMemberus-gaap:TechnologyBasedIntangibleAssetsMember2020-07-012020-09-300001637761us-gaap:CostOfSalesMemberus-gaap:TechnologyBasedIntangibleAssetsMember2019-07-012019-09-300001637761us-gaap:CostOfSalesMemberus-gaap:TechnologyBasedIntangibleAssetsMember2020-01-012020-09-300001637761us-gaap:CostOfSalesMemberus-gaap:TechnologyBasedIntangibleAssetsMember2019-01-012019-09-300001637761us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2020-09-300001637761us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2020-09-300001637761us-gaap:FairValueMeasurementsRecurringMember2020-09-300001637761us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2019-12-310001637761us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2019-12-310001637761us-gaap:FairValueMeasurementsRecurringMember2019-12-310001637761us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2019-12-310001637761spne:MilestonePaymentMember2016-09-260001637761spne:RoyaltypaymentMember2016-09-260001637761us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2020-06-300001637761us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2020-07-012020-09-300001637761us-gaap:FairValueMeasurementsRecurringMemberus-gaap:SellingGeneralAndAdministrativeExpensesMemberus-gaap:FairValueInputsLevel3Member2020-07-012020-09-300001637761us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2020-01-012020-09-300001637761us-gaap:FairValueMeasurementsRecurringMemberus-gaap:SellingGeneralAndAdministrativeExpensesMemberus-gaap:FairValueInputsLevel3Member2020-01-012020-09-3000016377612020-07-282020-07-2800016377612020-08-172020-08-1700016377612020-01-1000016377612020-01-102020-01-1000016377612018-02-012018-03-220001637761spne:A2015PlanMember2020-09-300001637761spne:A2018PlanMember2020-09-300001637761spne:A2020PlanMember2020-09-300001637761spne:RestrictedStockAwardsandPerformanceStockMember2020-01-012020-09-300001637761spne:RestrictedStockAwardsandPerformanceStockMember2019-01-012019-09-300001637761us-gaap:RestrictedStockMember2020-07-012020-09-300001637761us-gaap:RestrictedStockMember2020-01-012020-09-300001637761us-gaap:RestrictedStockMember2019-01-012019-09-300001637761us-gaap:RestrictedStockMember2019-07-012019-09-300001637761us-gaap:RestrictedStockUnitsRSUMember2020-07-012020-09-300001637761us-gaap:RestrictedStockUnitsRSUMember2020-01-012020-09-300001637761us-gaap:RestrictedStockUnitsRSUMember2019-07-012019-09-300001637761us-gaap:RestrictedStockUnitsRSUMember2019-01-012019-09-300001637761spne:RestrictedStockAwardsandPerformanceStockMember2020-09-300001637761us-gaap:EmployeeStockOptionMember2020-07-012020-09-300001637761us-gaap:EmployeeStockOptionMember2020-01-012020-09-300001637761us-gaap:EmployeeStockOptionMember2019-01-012019-09-300001637761us-gaap:EmployeeStockOptionMember2019-07-012019-09-300001637761us-gaap:EmployeeStockOptionMember2020-09-300001637761spne:EmployeeStockPurchasePlanMemberus-gaap:EmployeeStockMember2020-01-012020-09-300001637761spne:EmployeeStockPurchasePlanMemberus-gaap:EmployeeStockMember2020-09-300001637761spne:EmployeeStockPurchasePlanMemberus-gaap:EmployeeStockMember2018-12-310001637761spne:EmployeeStockPurchasePlanMemberus-gaap:EmployeeStockMember2018-11-020001637761spne:EmployeeStockPurchasePlanMemberus-gaap:EmployeeStockMember2019-01-012019-09-300001637761spne:EmployeeStockPurchasePlanMember2020-07-012020-09-300001637761spne:EmployeeStockPurchasePlanMember2019-07-012019-09-300001637761spne:EmployeeStockPurchasePlanMember2020-01-012020-09-300001637761spne:EmployeeStockPurchasePlanMember2019-01-012019-09-300001637761us-gaap:AccountingStandardsUpdate201602Member2020-01-0100016377612020-01-01spne:product0001637761country:USspne:OrthobiologicsMember2020-07-012020-09-300001637761spne:OrthobiologicsMemberspne:InternationalMember2020-07-012020-09-300001637761spne:OrthobiologicsMember2020-07-012020-09-300001637761country:USspne:OrthobiologicsMember2020-01-012020-09-300001637761spne:OrthobiologicsMemberspne:InternationalMember2020-01-012020-09-300001637761spne:OrthobiologicsMember2020-01-012020-09-300001637761spne:SpinalFusionHardwareMembercountry:US2020-07-012020-09-300001637761spne:SpinalFusionHardwareMemberspne:InternationalMember2020-07-012020-09-300001637761spne:SpinalFusionHardwareMember2020-07-012020-09-300001637761spne:SpinalFusionHardwareMembercountry:US2020-01-012020-09-300001637761spne:SpinalFusionHardwareMemberspne:InternationalMember2020-01-012020-09-300001637761spne:SpinalFusionHardwareMember2020-01-012020-09-300001637761country:US2020-07-012020-09-300001637761spne:InternationalMember2020-07-012020-09-300001637761country:US2020-01-012020-09-300001637761spne:InternationalMember2020-01-012020-09-300001637761country:USspne:OrthobiologicsMember2019-07-012019-09-300001637761spne:OrthobiologicsMemberspne:InternationalMember2019-07-012019-09-300001637761spne:OrthobiologicsMember2019-07-012019-09-300001637761country:USspne:OrthobiologicsMember2019-01-012019-09-300001637761spne:OrthobiologicsMemberspne:InternationalMember2019-01-012019-09-300001637761spne:OrthobiologicsMember2019-01-012019-09-300001637761spne:SpinalFusionHardwareMembercountry:US2019-07-012019-09-300001637761spne:SpinalFusionHardwareMemberspne:InternationalMember2019-07-012019-09-300001637761spne:SpinalFusionHardwareMember2019-07-012019-09-300001637761spne:SpinalFusionHardwareMembercountry:US2019-01-012019-09-300001637761spne:SpinalFusionHardwareMemberspne:InternationalMember2019-01-012019-09-300001637761spne:SpinalFusionHardwareMember2019-01-012019-09-300001637761country:US2019-07-012019-09-300001637761spne:InternationalMember2019-07-012019-09-300001637761country:US2019-01-012019-09-300001637761spne:InternationalMember2019-01-012019-09-30

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549 
FORM 10-Q 
(Mark One)
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2020
or
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from              to             
COMMISSION FILE NO. 001-36905
SeaSpine Holdings Corporation
(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)
Delaware 47-3251758
(STATE OR OTHER JURISDICTION OF
INCORPORATION OR ORGANIZATION)
 (I.R.S. EMPLOYER
IDENTIFICATION NO.)
5770 Armada Drive, Carlsbad, CA 92008
(Address of principal executive offices) (zip code)
REGISTRANT’S TELEPHONE NUMBER, INCLUDING AREA CODE: (760727-8399
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common StockSPNEThe Nasdaq Global Select Market
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  x   No  o  
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes  x    No  o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company”, and "emerging growth company" in Rule 12b-2 of the Exchange Act.



Large accelerated fileroAccelerated filer
Non-accelerated filero Smaller reporting company
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes    No  ý
The number of shares of the registrant’s common stock, $0.01 par value, outstanding as of November 4, 2020 was 27,633,147.




SEASPINE HOLDINGS CORPORATION
INDEX
 Page
Number




PART I. FINANCIAL INFORMATION
Item 1. Financial Statements
SEASPINE HOLDINGS CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
(In thousands, except per share data)
 
 Three Months Ended September 30,Nine Months Ended September 30,
 2020201920202019
Total revenue, net$43,209 $39,888 $107,909 $115,344 
Cost of goods sold14,074 14,407 39,545 42,303 
Gross profit29,135 25,481 68,364 73,041 
Operating expenses:
Selling and marketing22,163 21,682 59,652 60,552 
General and administrative8,908 8,452 26,307 24,498 
Research and development3,917 3,896 11,786 10,995 
Intangible amortization793 792 2,377 2,377 
Impairment of intangible assets  1,325 4,993 
Total operating expenses35,781 34,822 101,447 103,415 
Operating loss(6,646)(9,341)(33,083)(30,374)
Other income (expense), net136 (97)377 (49)
Loss before income taxes(6,510)(9,438)(32,706)(30,423)
Provision for income taxes64 225 132 265 
Net loss$(6,574)$(9,663)$(32,838)$(30,688)
Net loss per share, basic and diluted$(0.24)$(0.51)$(1.21)$(1.62)
Weighted average shares used to compute basic and diluted net loss per share27,536 19,051 27,082 18,947 
The accompanying notes are an integral part of these condensed consolidated financial statements.
4



SEASPINE HOLDINGS CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
(Unaudited)
(In thousands)
 Three Months Ended September 30,Nine Months Ended September 30,
 2020201920202019
Net loss$(6,574)$(9,663)$(32,838)$(30,688)
Other comprehensive (loss) income
Foreign currency translation adjustments347 (327)325 (388)
Unrealized (loss) gain on investments(70)(9)31 5 
Comprehensive loss$(6,297)$(9,999)$(32,482)$(31,071)
The accompanying notes are an integral part of these condensed consolidated financial statements.


5





SEASPINE HOLDINGS CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)
(In thousands, except par value data)
September 30, 2020December 31, 2019
ASSETS
Current assets:
Cash and cash equivalents
$78,188 $20,199 
Short-term investments
15,043  
Trade accounts receivable, net of allowances of $371 and $111
23,352 24,902 
Inventories, net
51,645 47,155 
Prepaid expenses and other current assets
2,152 3,906 
  Total current assets
170,380 96,162 
Property, plant and equipment, net28,109 25,751 
Right of use assets8,013  
Intangible assets, net14,682 19,173 
Other assets558 632 
Total assets$221,742 $141,718 
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Short-term debt
$6,173 $ 
Accounts payable, trade
8,092 7,448 
Accrued compensation
7,335 7,879 
Accrued commissions
7,028 7,843 
Contingent consideration liabilities
49 1,864 
Short-term lease liability
2,130  
Other accrued expenses and current liabilities
5,071 5,444 
  Total current liabilities
35,878 30,478 
Long-term lease liability7,230  
Other liabilities96 1,480 
Total liabilities43,204 31,958 
Commitments and contingencies
Stockholders' equity:
Preferred stock, $0.01 par value; 15,000 authorized; no shares issued and outstanding at September 30, 2020 and December 31, 2019
  
Common stock, $0.01 par value; 60,000 authorized; 27,621 and 19,124 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively
276 191 
Additional paid-in capital385,386 284,211 
Accumulated other comprehensive income1,790 1,434 
Accumulated deficit(208,914)(176,076)
Total stockholders' equity178,538 109,760 
Total liabilities and stockholders' equity$221,742 $141,718 
The accompanying notes are an integral part of these condensed consolidated financial statements.


6



SEASPINE HOLDINGS CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
(In thousands)
7



 Nine Months Ended September 30,
 20202019
OPERATING ACTIVITIES:
Net loss$(32,838)$(30,688)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization7,929 7,929 
Instrument replacement expense 1,555 1,602 
Impairment of intangible assets1,325 4,993 
Impairment of spinal instruments210 30 
Provision for excess and obsolete inventories3,365 2,358 
Stock-based compensation7,934 5,907 
Loss/(gain) from change in fair value of contingent consideration liabilities160 (571)
Other49 233 
Changes in assets and liabilities:
Accounts receivable1,606 (3,531)
Inventories(6,436)(6,413)
Prepaid expenses and other current assets1,755 (236)
Other non-current assets(10)(2)
Accounts payable140 2,117 
Accrued commissions(825)1,918 
Other accrued expenses and current liabilities66 (1,013)
Other non-current liabilities(17)237 
Net cash used in operating activities(14,032)(15,130)
INVESTING ACTIVITIES:
Purchases of property and equipment(9,571)(10,337)
Additions to technology assets(850) 
Purchases of short-term investments(25,007) 
Maturities of short-term investments10,000 25,000 
Net cash (used in) provided by investing activities(25,428)14,663 
FINANCING ACTIVITIES:
Proceeds from Paycheck Protection Program Loan7,173  
Repayments of Paycheck Protection Program Loan(1,000) 
Proceeds from issuance of common stock- employee stock purchase plan698 671 
Proceeds from exercise of stock options1,073 230 
Proceeds from issuance of common stock, net of offering costs91,622  
Repurchases of common stock for income tax withheld upon vesting of restricted stock awards and restricted stock units(2,069)(2,070)
Payment of contingent consideration liabilities in connection with acquisition of
business
(109)(98)
Net cash provided by (used in) financing activities97,388 (1,267)
Effect of exchange rate changes on cash and cash equivalents61 (185)
Net change in cash and cash equivalents57,989 (1,919)
Cash and cash equivalents at beginning of period20,199 24,233 
Cash and cash equivalents at end of period$78,188 $22,314 
Supplemental cash flow information:
Interest paid$126 $115 
Income taxes paid$115 $98 
Non-cash investing activities:
Property and equipment in liabilities$1,187 $1,358 
Non-cash financing activities:
Settlement of contingent closing consideration liabilities with stock issuance in connection with acquisition of business $2,000 $ 
The accompanying notes are an integral part of these condensed consolidated financial statements.
8



SEASPINE HOLDINGS CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF EQUITY
(Unaudited)
(In thousands)
 Common Stock Additional Accumulated OtherTotal
Number of Paid-InComprehensive AccumulatedStockholders'
Shares Amount CapitalIncomeDeficit Equity
Balance December 31, 201919,124 $191 $284,211 $1,434 $(176,076)$109,760 
Net loss— — — — (12,551)(12,551)
Foreign currency translation adjustment— — — (164)— (164)
Unrealized gain on short-term investments— — — 190 — 190 
Restricted stock issued213 2 — — — 2 
Issuance of common stock - public offering7,820 78 91,544 — — 91,622 
Issuance of common stock - exercise of stock options80 1 901 — — 902 
Repurchases of common stock for income tax withheld upon vesting of restricted stock awards and restricted stock units— — (1,855)— — (1,855)
Stock-based compensation— — 1,983 — — 1,983 
Balance March 31, 202027,237 272 376,784 1,460 (188,627)189,889 
Net loss— — — — (13,713)(13,713)
Foreign currency translation adjustment— — — 142 — 142 
Unrealized loss on short-term investments— — — (89)— (89)
Restricted stock issued79 1 (1)— —  
Issuance of common stock under employee stock purchase plan78 1 697 — — 698 
Issuance of common stock- exercise of stock options5  46 — — 46 
Repurchases of common stock for income tax withheld upon vesting of restricted stock awards and restricted stock units — (43)— — (43)
Stock-based compensation— — 2,769 — — 2,769 
Balance June 30, 202027,399 274 380,252 1,513 (202,340)179,699 
Net loss— — — — (6,574)(6,574)
Foreign currency translation adjustment— — — 347 — 347 
Unrealized loss on short-term investments— — — (70)— (70)
Restricted stock issued33 — — — —  
Issuance of common stock- NLT Spine Ltd contingent consideration176 2 1,998 — — 2,000 
Issuance of common stock- exercise of stock options13 — 125 — — 125 
Repurchases of common stock for income tax withheld upon vesting of restricted stock awards and restricted stock units — (171)— — (171)
Stock-based compensation— — 3,182 — — 3,182 
Balance September 30, 202027,621 276 385,386 1,790 (208,914)178,538 
9



 Common Stock Additional Accumulated OtherTotal
Number of Paid-InComprehensive AccumulatedStockholders'
Shares Amount CapitalIncomeDeficit Equity
Balance December 31, 201818,669 $187 $277,096 $1,602 $(136,800)$142,085 
Net loss— — — — (8,989)(8,989)
Foreign currency translation adjustment— — — (169)— (169)
Unrealized gain on short-term investments— — — 11 — 11 
Restricted stock issued216 2  — — 2 
Issuance of common stock- exercise of stock options11  143 — — 143 
Repurchases of common stock for income tax withheld upon vesting of restricted stock awards and restricted stock units — (1,851)— — (1,851)
Stock-based compensation— — 1,947 — — 1,947 
Balance March 31, 201918,896 189 277,335 1,444 (145,789)133,179 
Net loss— — — — (12,036)(12,036)
Foreign currency translation adjustment— — — 108 — 108 
Unrealized gain on short-term investments— — — 3 — 3 
Restricted stock issued71 1  — — 1 
Issuance of common stock under employee stock purchase plan64 1 670 — — 671 
Issuance of common stock- exercise of stock options5 — 76 — — 76 
Repurchases of common stock for income tax withheld upon vesting of restricted stock awards and restricted stock units — (57)— — (57)
Stock-based compensation— — 1,970 — — 1,970 
Balance June 30, 201919,036 191 279,994 1,555 (157,825)123,915 
Net loss— — — — (9,663)(9,663)
Foreign currency translation adjustment— — — (327)— (327)
Unrealized loss on short-term investments— — — (9)— (9)
Restricted stock issued23 — — — —  
Issuance of common stock- exercise of stock options1 — 10 — — 10 
Repurchases of common stock for income tax withheld upon vesting of restricted stock awards and restricted stock units— — (164)— — (164)
Stock-based compensation— — 1,990 — — 1,990 
Balance September 30, 201919,060 191 281,830 1,219 (167,488)115,752 
The accompanying notes are an integral part of these condensed consolidated financial statements.
10



SEASPINE HOLDINGS CORPORATION
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
1. BUSINESS AND BASIS OF PRESENTATION
Business
SeaSpine Holdings Corporation was incorporated in Delaware on February 12, 2015 in connection with the spin-off of the orthobiologics and spinal implant business of Integra LifeSciences Holdings Corporation, a diversified medical technology company. The spin-off occurred on July 1, 2015. Unless the context indicates otherwise, (i) references to "SeaSpine" or the "Company" refer to SeaSpine Holdings Corporation and its wholly-owned subsidiaries, and (ii) references to "Integra" refer to Integra LifeSciences Holdings Corporation and its subsidiaries other than SeaSpine.
SeaSpine is a global medical technology company focused on the design, development and commercialization of surgical solutions for the treatment of patients suffering from spinal disorders. SeaSpine has a comprehensive portfolio of orthobiologics and spinal implant solutions to meet the varying combinations of products that neurosurgeons and orthopedic spine surgeons need to perform fusion procedures in the lumbar, thoracic and cervical spine. The Company believes this broad combined portfolio of orthobiologics and spinal implant products is essential to meet the “complete solution” requirements of such surgeons.
Basis of Presentation and Principles of Consolidation
The Company prepared the unaudited interim condensed consolidated financial statements included in this report in accordance with accounting principles generally accepted in the U.S. (GAAP) for interim financial information and the rules and regulations of the Securities and Exchange Commission (SEC) related to quarterly reports on Form 10-Q.
The Company’s financial statements are presented on a consolidated basis. The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. Intercompany accounts and transactions have been eliminated in consolidation. The unaudited interim condensed consolidated financial statements do not include all information and disclosures required by GAAP for annual audited financial statements and should be read with the Company’s consolidated financial statements and notes thereto for the year ended December 31, 2019 included in the Company’s Annual Report on Form 10-K filed with the SEC. In the opinion of management, the unaudited interim condensed consolidated financial statements included in this report have been prepared on the same basis as the Company's audited consolidated financial statements and include all adjustments (consisting only of normal recurring adjustments) necessary for a fair statement of the financial position, results of operations, cash flows, and statement of equity for periods presented. The results for the three and nine months ended September 30, 2020 are not necessarily indicative of the results expected for the full year. In addition, the full extent to which the COVID-19 pandemic will directly or indirectly impact the Company's business, results of operations and financial condition, including revenues, expenses, manufacturing, research and development costs and employee-related compensation, will depend on future developments that are highly uncertain and cannot be predicted. See Note 2. Summary of Significant Accounting Policies-Use of Estimates, below. The condensed consolidated balance sheet as of December 31, 2019 was derived from the audited consolidated balance sheet for the year ended December 31, 2019. Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on the reported results of operations.
Under current SEC rules, generally, a company qualifies as a "smaller reporting company" if it has a public float of less than $250 million as of the last business day of its most recently completed second fiscal quarter. If a company qualifies as a smaller reporting company on that date, it may elect to reflect that determination and use the smaller reporting company scaled disclosure accommodations in its subsequent SEC filings until the beginning of the first quarter of the fiscal year following the date it determines it does not qualify as a smaller reporting company. The Company's public float as of June 30, 2020, the last business day of its most recent second fiscal quarter, was less than $250 million, and as such, the Company qualifies as a smaller reporting company, elected to reflect that determination and intends to use certain of the scaled disclosure accommodations in its SEC filings made during and for each of the years ended December 31, 2020 and 2021.
Concentration of Risk
Integra and PcoMed, LLC (PcoMed) entered into a supply agreement in May 2013 (the Supply Agreement), which was subsequently assigned to the Company by Integra in May 2015. For the nine months ending September 30, 2020, the sales of products incorporating the NanoMetalene® technology licensed and supplied to the Company pursuant to the Supply Agreement exceeded 10% of the Company's revenue.
11

SEASPINE HOLDINGS CORPORATION
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)
Pursuant to the Supply Agreement, PcoMed granted the Company a worldwide exclusive license to sell certain of its products treated with certain proprietary PcoMed technology (Treatment) for use in the spinal interbody and intervertebral market (Treated Products). PcoMed serves as the sole supplier of the Treatment. As consideration for the license and the Treatment, the Company paid to PcoMed initial milestone payments prior to the initial sale of any Treated Products and the Company will pay PcoMed a low single digit royalty on the Company’s net sales of all Treated Products. In the event the Company fails to meet any of its payment obligations, the license will, at PcoMed’s option and following a cure period, convert to a non-exclusive license. The Supply Agreement contains customary representations and termination provisions, including for material breach and bankruptcy. Each of the Company and PcoMed retain the rights to their respective intellectual property.
The Company's financial instruments that are exposed to concentrations of credit risk consist primarily of cash. Cash balances are maintained primarily at major financial institutions in the United States and exceed the regulatory limit of $250,000 insured by the Federal Deposit Insurance Corporation (FDIC). The Company has not experienced any credit losses associated with its cash balances.
2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Use of Estimates
Preparing consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent liabilities, and the reported amounts of revenues and expenses. Significant estimates affecting amounts reported or disclosed in the consolidated financial statements include allowances for doubtful accounts receivable and sales returns and other credits, net realizable value of inventories, discount rates and estimated projected cash flows used to value and test impairments of identifiable intangible and long-lived assets, assumptions related to the timing and probability of product launch dates, discount rates matched to the estimated timing of payments, probability of success rates and discount adjustments on the related cash flows for contingent considerations in business combinations, depreciation and amortization periods for identifiable intangible and long-lived assets, computation of taxes, valuation allowances recorded against deferred tax assets, the valuation of stock-based compensation and loss contingencies. These estimates are based on historical experience and on various other assumptions believed to be reasonable under the current circumstances. Actual results could differ from these estimates.
The full extent to which the COVID-19 pandemic will directly or indirectly impact the Company's business, results of operations and financial condition, including revenues, expenses, manufacturing, research and development costs and employee-related compensation, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain it or treat COVID-19, as well as the economic impact on local, regional, national and international customers and markets. The Company has made estimates of the impact of the pandemic within its financial statements and there may be changes to those estimates in future periods. Actual results may differ from these estimates.
Recent Accounting Standards Not Yet Adopted
The Company qualifies as an “emerging growth company” (EGC) under the Jumpstart Our Business Startups (JOBS) Act and elected to take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act of 1933, as amended, which permits EGCs to defer compliance with new or revised accounting standards until non-issuers must comply with such standards. Accordingly, so long as the Company continues to qualify as an EGC, the Company will not have to adopt or comply with new or revised accounting standards until non-issuers must adopt or comply with such standards. The Company will no longer qualify as an EGC on December 31, 2020, the last day of the fiscal year following the fifth year after its spin-off from Integra.
In June 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU or Update) No. 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which requires credit losses on most financial assets measured at amortized cost, including trade receivables, and certain other instruments to be measured using an expected credit loss model, referred to as the current expected credit loss model. Under this model, entities will estimate credit losses over the entire contractual term of the instrument. The new standard will be effective for the Company beginning January 1, 2023. The FASB subsequently issued other related ASUs that amend ASU No. 2016-13 to provide clarification and additional guidance. The Company is evaluating the impact of this standard on its consolidated financial statements.
In August 2018, the FASB issued Update No. 2018-15, Intangibles-Goodwill and Other-Internal Use Software (Subtopic 350-40). The amendments in this Update align the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain
12

SEASPINE HOLDINGS CORPORATION
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)
internal-use software (and hosting arrangements that include an internal-use software license). The new standard will be effective for the Company beginning on January 1, 2021. Early adoption is permitted. The Company is evaluating the impact of this standard on its consolidated financial statements.
In April 2019, the FASB issued Update No. 2019-04, Codification Improvements to Topic 326, Financial Instruments-Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments. This Update includes several amendments to the FASB Accounting Standards Codification (Codification) intended to clarify, improve, or correct errors therein. Some amendments do not require transition guidance and are effective upon issuance. The amendments requiring transition guidance have the same effective date as Update No. 2016-13 and will be effective for the Company beginning on January 1, 2023. The Company is evaluating the impact of this standard on its consolidated financial statements.
Recently Adopted Accounting Standards
In February 2016, the FASB issued Update No. 2016-02, Leases (Topic 842). The new standard requires lessees to recognize lease liabilities and corresponding right-of-use assets for all leases with lease terms of greater than twelve months. It also changes the definition of a lease and expands the disclosure requirements of lease arrangements. The new standard must be adopted using the modified retrospective approach. In July 2018, the FASB issued Update No. 2018-10, Codification Improvements to Topic 842 (Leases) and Update No. 2018-11, Leases (Topic 842): Targeted Improvements. In March 2019, the FASB issued Update No. 2019-01, Leases (Topic 842): Codification Improvements. In November 2019, the FASB issued Update No. 2019-10, Financial Instruments - Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842): Effective Dates, which modifies the effective dates for Topic 842. The amendments in Updates Nos. 2018-10, 2018-11, 2019-01, and 2019-10 provide additional clarification and implementation guidance on certain aspects of Topic 842 and have the same effective date and transition requirements as ASU 2019-10. The Company early adopted the new standard beginning on January 1, 2020. The Company adopted the new standard electing the optional transition method that allows for a cumulative-effect adjustment in the period of adoption and did not restate prior periods. The Company applied the transition package of practical expedients allowed by the standard. As a result of the Company’s adoption of the new standard, the Company recorded right-of-use assets and lease liabilities of $9.1 million and $10.5 million, respectively, for existing operating leases in the consolidated balance sheets at January 1, 2020. Additionally, the Company reversed $1.4 million of deferred rent liabilities previously recorded under the previous accounting guidance. The adoption of this new standard had no material impact on its consolidated results of operations or cash flows.
In June 2018, the FASB issued Update No. 2018-07, Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting. This Update requires an entity to apply the requirements of Topic 718 to nonemployee awards except for specific guidance on inputs to an option pricing model and the attribution of cost (that is, the period of time over which share-based payment awards vest and the pattern of cost recognition over that period). The amendments specify that Topic 718 applies to all share-based payment transactions in which a grantor acquires goods or services to be used or consumed in a grantor’s own operations by issuing share-based payment awards. The amendments also clarify that Topic 718 does not apply to share-based payments used to effectively provide (1) financing to the issuer or (2) awards granted in conjunction with selling goods or services to customers as part of a contract accounted for under Topic 606. The new standard was effective for the Company beginning on January 1, 2020. The adoption of this new standard had no material impact on its consolidated financial statements.
In August 2018, the FASB issued Update No. 2018-13, Fair Value Measurement (Topic 820)-Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement. The amendments in this Update modify the disclosure requirements on fair value measurements in Topic 820 based on the concepts in the Concepts Statement including the consideration of costs and benefits. The new standard was effective for the Company beginning on January 1, 2020. The adoption of this new standard had no material impact on its consolidated financial statements.
In March 2020, the FASB issued Update No. 2020-04, Reference Rate Reform (Topic 848), Facilitation of the Effects of Reference Rate Reform on Financial Reporting. The amendments in this Update apply only to contracts, hedging relationships, and other transactions that reference LIBOR, or another reference rate expected to be discontinued, due to the reference rate reform. The new standard was effective for the Company beginning March 12, 2020. The adoption of this new standard had no material impact on its consolidated financial statements.
13

SEASPINE HOLDINGS CORPORATION
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)
Net Loss Per Share
Basic and diluted net loss per share was calculated using the weighted-average number of shares of common stock outstanding during the period. The weighted average number of shares used to compute diluted net loss per share excludes any assumed issuance of common stock upon exercise of stock options, any assumed issuance of common stock under restricted stock awards or units, and any assumed issuances under the Company's employee stock purchase plan, because the effect, in each case, would be antidilutive. Common stock equivalents of 4.3 million and 3.6 million shares for the nine months ended September 30, 2020 and 2019, respectively, were excluded from the calculation because of their antidilutive effect.
3. DEBT AND INTEREST
Credit Agreement
In December 2015, the Company entered into a three-year credit facility with Wells Fargo Bank, National Association, which was amended in October 2016, in July 2018, and in July 2020 (as amended, the Credit Facility). The Credit Facility provides an asset-backed revolving line of credit of up to $30.0 million with a maturity date of July 27, 2021, which is subject to a one-time, one-year extension at the Company's election. In addition, under the Credit Facility, at any time through July 27, 2021, the Company may increase the $30.0 million borrowing limit by up to an additional $10.0 million, subject to the Company having sufficient amounts of eligible accounts receivable and inventory and to customary conditions precedent, including obtaining the commitment of lenders to provide such additional amount. In connection with entering into the Credit Facility, the Company was required to become a guarantor and to provide a security interest in substantially all its assets for the benefit of the counterparty.
There were no amounts outstanding under the Credit Facility at September 30, 2020 or December 31, 2019. At September 30, 2020, the Company had $21.2 million of current borrowing capacity under the Credit Facility before the requirement to maintain the minimum fixed charge coverage ratio as discussed below. Debt issuance costs and legal fees related to the Credit Facility totaling $0.6 million were recorded as a deferred asset and are being amortized ratably over the term of the arrangement.
Borrowings under the Credit Facility accrue interest at the rate then applicable to base rate loans (as customarily defined), unless and until converted into LIBOR rate loans (as customarily defined) in accordance with the Credit Facility. Borrowings bear interest at a floating annual rate equal to (a) during any month for which the Company's average excess availability (as customarily defined) is greater than $20.0 million, (i) base rate plus 1.25 percentage points for base rate loans and (ii) LIBOR rate plus 2.25 percentage points for LIBOR rate loans, (b) during any month for which the Company's average excess availability is greater than $10.0 million but less than or equal to $20.0 million, (i) base rate plus 1.50 percentage points for base rate loans and (ii) LIBOR rate plus 2.50 percentage points for LIBOR rate loans and (c) during any month for which the Company's average excess availability is less than or equal to $10.0 million, (i) base rate plus 1.75 percentage points for base rate loans and (ii) LIBOR rate plus 2.75 percentage points for LIBOR rate loans. The Company also pays an unused line fee based on the average amount borrowed under the Credit Facility for the most recently completed month. If such average amount is 25% or greater of the maximum borrowing capacity, the unused fee will be equal to 0.375% per annum of the amount unused under the Credit Facility, and if such average amount is less than 25%, the unused line fee will be equal to 0.50% per annum of the amount unused under the Credit Facility. The unused line fee is due on the first day of each month.
The Credit Facility contains various customary affirmative and negative covenants, including prohibiting the Company from incurring indebtedness without the lender’s consent. The Credit Facility also includes a financial covenant that requires the Company to maintain a minimum fixed charge coverage ratio of 1.10 to 1.00 for the applicable measurement period, if the Company's Total Liquidity (as defined in the Credit Facility) is less than $5.0 million. The Company was in compliance with all applicable covenants at September 30, 2020.
The Credit Facility also includes customary events of default, including events of default relating to non-payment of amounts due under the Credit Facility, material inaccuracy of representations and warranties, violation of covenants, bankruptcy and insolvency, failure to comply with health care laws, violation of certain of the Company’s existing agreements, and the occurrence of a change of control. Under the Credit Facility, if an event of default occurs, the lender will have the right to terminate the commitments and accelerate the maturity of any loans outstanding.
14

SEASPINE HOLDINGS CORPORATION
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)
Paycheck Protection Program
In April 2020, due to the economic uncertainty resulting from the impact of the COVID-19 pandemic on the Company's operations and to support its ongoing operations and retain all employees, the Company applied for a loan under the Paycheck Protection Program (PPP) of the Coronavirus Aid, Relief, and Economic Security Act (CARES Act). The Company received a loan in the original principal amount of $7.2 million. The Company subsequently repaid $1.0 million of the loan. Under the terms of the PPP, subject to specified limitations, the loan may be forgiven if the proceeds are used in accordance with the CARES Act. The Company used the loan proceeds for purposes consistent with the terms of the PPP and has applied for forgiveness of the entire loan; however, no assurance is provided that the Company will obtain forgiveness of the loan in whole or in part. Any unforgiven portion of the loan is payable over two years at an interest rate of 1%, with a deferral of payments for the first six months from the date of the loan.
4. INVESTMENTS
The amortized cost, estimated fair value and gross unrealized gains and losses on investments are shown in the table below:
September 30, 2020
Amortized CostGross UnrealizedFair Value
Gains(Losses)
(In thousands)
U.S. Treasury Bills$15,012 $31 $ $15,043 
There were no realized gains or losses during the three and nine months ended September 30, 2020. As of December 31, 2019, there were no short-term investments.
5. INVENTORIES
Inventories consisted of:
September 30, 2020December 31, 2019
 (In thousands)
Finished goods$36,767 $30,042 
Work in process8,525 10,847 
Raw materials6,353 6,266 
$51,645 $47,155 
6. PROPERTY, PLANT AND EQUIPMENT
Property, plant and equipment are stated at historical cost less accumulated depreciation and amortization and any impairment charges. The Company provides for depreciation using the straight-line method over the estimated useful lives of the assets. Leasehold improvements are amortized over the lesser of the lease term or the useful life. The cost of major additions and improvements is capitalized, while maintenance and repair costs that do not improve or extend the lives of the respective assets are charged to operations as incurred. The cost of computer software obtained for internal use is accounted for in accordance with the Codification 350-40, Internal-Use Software.
The cost of purchased spinal instruments which the Company consigns to hospitals and independent sales agents to support surgeries is initially capitalized as construction in progress. The amount is either then reclassified to spinal instruments and sets, and depreciation is initiated when instruments are put together in a newly built set with spinal implants, or directly expensed for the instruments used to replace damaged instruments in an existing set. The depreciation expense and direct expense for replacement instruments are recorded in selling and marketing expense.
15

SEASPINE HOLDINGS CORPORATION
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)
Property, plant and equipment balances and corresponding useful lives were as follows:
September 30, 2020December 31, 2019Useful Lives
 (In thousands)
Leasehold improvements$5,976 $5,878 Shorter of lease term or useful life
Machinery and production equipment9,295 8,562 3-10years
Spinal instruments and sets31,636 25,511 4-5years
Information systems and hardware7,784 7,442 3-7years
Furniture and fixtures1,456 1,412 3-5years
Construction in progress9,517 9,716 
     Total65,664 58,521 
Less accumulated depreciation and amortization(37,555)(32,770)
Property, plant and equipment, net$28,109 $25,751 
Depreciation and amortization expenses totaled $1.7 million and $1.3 million for the three months ended September 30, 2020 and 2019, respectively, and $4.8 million and $3.6 million for the nine months ended September 30, 2020 and 2019, respectively. The cost of purchased instruments used to replace damaged instruments in existing sets and recorded directly to instrument replacement expense totaled $0.6 million for each of the three months ended September 30, 2020 and 2019, and $1.6 million for each of the nine months ended September 30, 2020 and 2019.
For the nine months ended September 30, 2020, the Company recorded impairment charges to selling and marketing expense totaling $0.2 million against spinal instruments that are no longer expected to be placed into service. Impairment charges against spinal instruments recorded for the nine months ended September 30, 2019 were immaterial.

16

SEASPINE HOLDINGS CORPORATION
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)
7. IDENTIFIABLE INTANGIBLE ASSETS
Identifiable intangible assets are initially recorded at fair value at the time of acquisition, generally using an income or cost approach. The Company capitalizes costs incurred to renew or extend the term of recognized intangible assets and amortizes those costs over their expected useful lives.
Primarily as a result of an expected shift in future product revenue mix more toward a parallel expanding interbody device designed based on the Company’s internally developed technology and, in turn, lower future revenue anticipated for the lordotic expanding implant based on technology the Company acquired from N.L.T. Spine Ltd. (NLT) and NLT Spine, Inc., a wholly owned subsidiary of NLT, the Company's estimated future net sales associated with those NLT product technologies decreased. Accordingly, the Company evaluated the ongoing value of the product technology intangible assets associated with the acquisition of these assets. Based on this evaluation, the Company determined that intangible assets with a carrying amount of $1.6 million were no longer recoverable and were impaired, and the Company wrote those intangible assets down to their estimated fair value of $0.3 million at March 31, 2020. Significant estimates used in determining the estimated fair value include measurements estimating cash flows and determining the appropriate discount rate, which are considered Level 3 inputs under Codification 820.
The components of the Company’s identifiable intangible assets were:
 September 30, 2020
 Weighted
Average
Life
CostAccumulated
Amortization
Net
 (Dollars in thousands)
Product technology12 years32,641 $(29,509)$3,132 
Customer relationships12 years56,830 (45,280)11,550 
Trademarks/brand names300 (300) 
$89,771 $(75,089)$14,682 
 December 31, 2019
 Weighted
Average
Life
CostAccumulated
Amortization
Net
 (Dollars in thousands)
Product technology12 years$34,158 $(28,912)$5,246 
Customer relationships12 years56,830 (42,903)13,927 
Trademarks/brand names300 (300) 
$91,288 $(72,115)$19,173 
Annual amortization expense (including amounts reported in cost of goods sold) is expected to be approximately $4.2 million in 2020, $4.2 million in 2021, $4.1 million in 2022, $3.4 million in 2023, and $1.5 million in 2024. For the three months ended September 30, 2020 and 2019, amortization expense totaled $1.0 million and $1.2 million, respectively, and included $0.3 million and $0.4 million, respectively, of amortization of product technology intangible assets that is presented within cost of goods sold. Amortization expense totaled $3.2 million and $4.3 million for the nine months ended September 30, 2020 and 2019, respectively, and included $0.8 million and $1.9 million, respectively, of amortization of product technology intangible assets that is presented within cost of goods sold.

17

SEASPINE HOLDINGS CORPORATION
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)
8. FAIR VALUE MEASUREMENTS
The fair values of the Company’s assets and liabilities, including contingent consideration liabilities, are measured at fair value on a recurring basis, and are determined under the fair value categories as follows (in thousands):
TotalQuoted Price in Active Market (Level 1)Significant Other Observable Inputs (Level 2)Significant Unobservable Inputs (Level 3)
September 30, 2020:
Short-term investments$15,043 $15,043 $ $ 
    Contingent consideration liabilities- current$49 $ $ $49 
    Contingent consideration liabilities- non-current96   96 
Total contingent consideration$145 $ $ $145 
TotalQuoted Price in Active Market (Level 1)Significant Other Observable Inputs (Level 2)Significant Unobservable Inputs (Level 3)
December 31, 2019:
Short-term investments$ $ $ $ 
    Contingent consideration liabilities- current$1,864 $ $ $1,864 
    Contingent consideration liabilities- non-current230   230 
Total contingent consideration$2,094 $ $ $2,094 
Short-term investments are classified with Level 1 of the fair value hierarchy because they use quoted market prices in active markets for identical assets.
Under the terms of the 2016 asset purchase agreement between the Company and NLT, the Company is obligated to pay up to a maximum $5.0 million in milestone payments to NLT, payable at the Company's election in cash or in shares of its common stock. Such milestone payments are contingent on the Company's achievement of four independent events related to the commercialization of the product technologies the Company acquired in the transaction. To date, the Company achieved two of the milestones, one each during the three months ended June 30, 2020 and September 30, 2020, and paid the $2.0 million of milestone payments in shares of its common stock in July 2020 and August 2020, respectively. Additionally, the Company must pay royalty payments, in cash, to NLT equal to declining (over time) percentages of the Company’s future net sales of certain of the acquired product technologies not to exceed $43.0 million in the aggregate. The Company has the option to terminate any future obligation to make royalty payments by making a one-time cash payment to NLT of $18.0 million.
Contingent consideration liabilities are classified within Level 3 of the fair value hierarchy because they use significant unobservable inputs. For those liabilities, fair value is determined using a probability-weighted discounted cash flow model and significant inputs which are not observable in the market. The significant inputs include assumptions related to the timing and probability of the product launch dates, estimated future sales of the products, estimated commission rates, discount rates matched to the timing of payments, and probability of success rates.
The following table sets forth the changes in the estimated fair value of the Company’s liabilities measured on a recurring basis using significant unobservable inputs (Level 3). The loss from change in fair value of contingent milestone and royalty payments resulted from the timing of payments, success rates, the passage of time, updated discount rates matched to the estimated timing of payments, actual net sales of certain products for the three and nine months ended September 30, 2020, and estimated net sales for future royalty payment periods.
A change in estimated timing of payments, probability of success rates, or estimated net sales for future royalty payment periods would be expected to have a material impact on the fair value of contingent milestone and royalty payments.
18

SEASPINE HOLDINGS CORPORATION
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)
Three Months Ended September 30, 2020:(in thousands)
Balance as of June 30, 2020$2,106 
    Contingent consideration liabilities settled(2,037)
Loss from change in fair value of contingent consideration recorded in general and administrative expenses
76 
Fair value at September 30, 2020$145 
Nine Months Ended September 30, 2020:(in thousands)
Balance as of January 1, 2020$2,094 
    Contingent consideration liabilities settled(2,109)
Loss from change in fair value of contingent consideration recorded in general and administrative expenses
160 
Fair value at September 30, 2020$145 

19

SEASPINE HOLDINGS CORPORATION
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)
9. EQUITY AND STOCK-BASED COMPENSATION
Common Stock
On July 28, 2020 and August 17, 2020, the Company issued 100,100 shares and 75,585 shares of its common stock to NLT, respectively, as settlement of contingent milestone payments pursuant to the terms of the asset purchase agreement entered into with NLT in August 2016. See Note 8, "Fair Value Measurements" above.
In January 2020, the Company entered into an Underwriting Agreement with Piper Sandler & Co. and Canaccord Genuity LLC relating to the issuance and sale of 6,800,000 shares of the Company’s common stock at a price to the public of $12.50 per share, before underwriting discounts and commissions. Under the terms of that agreement, the Company granted the underwriters an option, exercisable for 30 days, to purchase up to an additional 1,020,000 shares of common stock. The underwriters exercised this option and the offering closed on January 10, 2020 with the sale of 7,820,000 shares of common stock, resulting in net proceeds to the Company of approximately $91.6 million, after deducting underwriting discounts and commissions and estimated offering expenses payable by the Company. The offering was made pursuant to the Company’s shelf registration statement on Form S-3 that was declared effective on May 22, 2019.
Equity Award Plans
As of June 30, 2015, Integra had stock options, restricted stock awards, performance stock awards, contract stock awards and restricted stock units outstanding under three plans, the 2000 Equity Incentive Plan, the 2001 Equity Incentive Plan, and the 2003 Equity Incentive Plan. In connection with the spin-off, Integra equity awards granted to individuals who became employees of SeaSpine were converted to equity awards denominated in SeaSpine common stock. In general, each post-conversion award is subject to the same terms and conditions as were applicable to the pre-conversion award.
In May 2015, the Company adopted the 2015 Incentive Award Plan, which was subsequently amended and restated with approval of the Company's stockholders. In February and March 2018, the Company's board of directors approved amendments to the plan that increased the share reserve by an aggregate of 2,726,000 shares over the then-existing share reserve thereunder, subject to stockholder approval. The Company's stockholders approved both amendments in May 2018. On April 13, 2020, the Company's board of directors approved an amendment to the plan that, among other things, increased the share reserve by an aggregate of 3,500,000 shares over the then-existing share reserve thereunder, subject to stockholder approval. The Company's stockholders approved the amendment on June 3, 2020 (the 2015 Incentive Award Plan, as amended and restated to date, the Restated Plan). Under the Restated Plan, the Company can grant its employees, non-employee directors and consultants incentive stock options and non-qualified stock options, restricted stock, performance stock, dividend equivalent rights, stock appreciation rights, stock payment awards and other incentive awards. The aggregate number of shares that may be issued or transferred pursuant to awards under the Restated Plan is the sum of (1) the number of shares issuable upon exercise or vesting of the number of Integra equity awards converted to the Company's equity awards under the Restated Plan as of the date of the spin-off and (2) 9,735,500 shares of its common stock in respect of awards granted under the Restated Plan. As of September 30, 2020, 3,955,478 shares were available for issuance under the Restated Plan.
In June 2018, the Company established the 2018 Employment Inducement Incentive Award Plan (the 2018 Inducement Plan). The terms of the 2018 Inducement Plan are substantially similar to the terms of the Restated Plan with these principal exceptions: (1) incentive stock options may not be granted under the 2018 Inducement Plan; (2) there are no annual limits on awards that may be issued to an individual under the 2018 Inducement Plan; (3) awards granted under the 2018 Inducement Plan are not required to be subject to any minimum vesting period; and (4) awards may be granted under the 2018 Inducement Plan only to those individuals and in those circumstances described below. An aggregate of 2,000,000 shares are reserved under the 2018 Inducement Plan. As of September 30, 2020, 1,914,793 shares were available for issuance under the 2018 Inducement Plan. As a result of the approval of the amendment to the Restated Plan by the Company's stockholders in June 2020, no awards will be granted under the 2018 Inducement Plan in the future.
In August 2020, the Company adopted the 2020 Employment Inducement Incentive Award Plan (the 2020 Inducement Plan). The terms of the 2020 Inducement Plan are substantially similar to the terms of the 2015 Incentive Award Plan with four principal exceptions: (1) incentive stock options may not be granted under the 2020 Inducement Plan; (2) there are no annual limits on awards that may be issued to an individual under the 2020 Inducement Plan; (3) awards granted under the 2020 Inducement Plan are not required to be subject to any minimum vesting period; and (4) awards may be granted under the 2020 Inducement Plan only to those individuals and in those circumstances described below. An aggregate of 2,000,000 shares are reserved under the 2020 Inducement Plan. As of September 30, 2020, 1,959,415 share were available for issuance under the 2020 Inducement Plan.
20

SEASPINE HOLDINGS CORPORATION
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)
Both the 2018 Inducement Plan and the 2020 Inducement Plan were adopted by the Company’s board of directors without stockholder approval pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules. In accordance with Rule 5635(c)(4) of the Nasdaq Listing Rules, awards under those plans may only be made to an employee who has not previously been an employee or member of the Company's board of directors or of any board of directors of any parent or subsidiary of the Company, or following a bona fide period of non-employment by the Company or a parent or subsidiary, if he or she is granted such award in connection with his or her commencement of employment with the Company or a subsidiary and such grant is an inducement material to his or her entering into employment with the Company or such subsidiary.
Forfeiture Rate Assumptions
Stock-based compensation expense related to all equity awards includes an estimate for forfeitures. The expected forfeiture rate of all equity-based compensation is based on historical experience of pre-vesting forfeitures on awards and options by each homogeneous group of shareowners. For awards and options granted to non-executive employees, the forfeiture rate is estimated to be 13% annually for the nine months ended September 30, 2020 and 14% annually for the nine months ended September 30, 2019. There is no forfeiture rate applied to awards or options granted to non-employee directors or executive employees because their pre-vesting forfeitures are anticipated to be highly unlikely. As individual awards and options become fully vested, stock-based compensation expense is adjusted to recognize actual forfeitures.
Restricted Stock Awards and Restricted Stock Units
Restricted stock award and restricted stock unit grants to employees generally have a requisite service period of three years, and restricted stock award and restricted stock unit grants to non-employee directors generally have a requisite service period of one year. Both are subject to graded vesting. The Company expenses the fair value of restricted stock awards and restricted stock units on an accelerated basis over the vesting period or requisite service period, whichever is shorter.
During the three and nine months ended September 30, 2020, there were 4,894 and 77,414 shares of restricted stock awards granted to non-employee directors. During the nine months ended September 30, 2019, there were 76,471 shares of restricted stock awards granted to non-employee directors. No restricted stock awards were granted to non-employee directors during the three months ended September 30, 2019. No restricted stock units were granted to non-employee directors during the three or nine months ended September 30, 2020 or 2019.
During the three and nine months ended September 30, 2020, 22,650 and 399,404 restricted stock units were granted to employees, respectively. During the three and nine months ended September 30, 2019, 34,100 and 252,710 restricted stock units were granted to employees, respectively. No restricted stock awards were granted to employees during the three or nine months ended September 30, 2020 or 2019.
As of September 30, 2020, there was approximately $3.9 million of unrecognized compensation expense related to the unvested portions of restricted stock awards and of restricted stock units. This expense is expected to be recognized over a weighted-average period of approximately 0.9 years.
Stock Options
Stock option grants to employees generally have a requisite service period of four years, and stock option grants to non-employee directors generally have a requisite service period of one year. Both are subject to graded vesting. The Company records stock-based compensation expense associated with stock options on an accelerated basis over the applicable vesting period within each grant and based on their fair value at the date of grant using the Black-Scholes-Merton option pricing model. There were 22,753 stock options granted during the three months ended September 30, 2020, and 943,003 and 434,708 stock options granted during the nine months ended September 30, 2020 and 2019, respectively. There were no stock options granted during the three months ended September 30, 2019. The following weighted-average assumptions were used in the calculation of fair value for options granted during the period indicated.
21

SEASPINE HOLDINGS CORPORATION
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)
Three Months Ended September 30,Nine Months Ended September 30,
202020202019
Expected dividend yield%%%
Risk-free interest rate0.2%1.3%2.5%
Expected volatility 52.6%46.4%30.2%
Expected term (in years)3.84.95.0
The Company considered that it has never paid, and does not currently intend to pay, cash dividends. The risk-free interest rates are derived from the U.S. Treasury yield curve in effect on the date of grant for instruments with a remaining term similar to the expected term of the options. The expected volatility is calculated based upon the historical volatility of the Company's share prices. The expected term is calculated using the historical weighted average term of the Company’s options.
As of September 30, 2020, there was approximately $2.4 million of unrecognized compensation expense related to unvested stock options. This expense is expected to be recognized over a weighted-average period of approximately 1.4 years.
Employee Stock Purchase Plan
In May 2015, the Company adopted the SeaSpine Holdings Corporation 2015 Employee Stock Purchase Plan, which was amended in November 2018, as described below (as amended, the ESPP). Under the ESPP, eligible employees may purchase shares of the Company’s common stock through payroll deductions of up to 15% of eligible compensation during an offering period. Generally, each offering period will be for 24 months as determined by the Company's board of directors. There are four six-month purchase periods in each offering period for contributions to be made and to be converted into shares at the end of the purchase period. In no event may an employee purchase more than 2,500 shares per purchase period based on the closing price on the first trading date of an offering period or more than $25,000 worth of stock during any calendar year. The purchase price for shares to be purchased under the ESPP is 85% of the lesser of the market price of the Company's common stock on the first trading date of an offering period or on any purchase date during an offering period (June 30 or December 31).
Subject to stockholder approval, on and effective as of November 2, 2018, the Company's board of directors approved an amendment to the ESPP pursuant to which the share reserve under the ESPP would increase from 400,000 shares to 800,000 shares. The Company's stockholders approved that amendment in May 2019. The ESPP is intended to qualify as an “employee stock purchase plan” within the meaning of Section 423 of the Internal Revenue Code of 1986, as amended (the IRC). The ESPP contains a restart feature, such that if the market price of the stock at the end of any six-month purchase period is lower than the market price at the original grant date of an offering period, that offering period will terminate after that purchase date, and a new two-year offering period will commence on the January 1 or July 1 immediately following the date the original offering period terminated. This restart feature was triggered on the purchase date that occurred on June 30, 2019, such that the offering period that commenced on January 1, 2019 was terminated, and a new two-year offering period commenced on July 1, 2019 and would end on June 30, 2021. This restart feature was triggered again on the purchase date that occurred on December 31, 2019, such that the offering periods that commenced on each of July 1, 2018 and July 1, 2019 were terminated, and a new two-year offering period commenced on January 1, 2020 and would end on December 31, 2021. This restart feature was triggered again on the purchase date that occurred on June 30, 2020, such that the offering period that commenced on January 1, 2020 was terminated, and a new two-year offering period commenced on July 1, 2020 and will end on June 30, 2022. The Company applied share-based payment modification accounting to the awards that were initially valued at the grant date to determine the amount of any incremental fair value associated with the modified awards. The impact to stock-based compensation expense for modifications during the nine months ended September 30, 2020 was immaterial.
During the nine months ended September 30, 2020 and 2019, there were 78,360 and 64,008 shares of common stock, respectively, purchased under the ESPP. The Company recognized $0.7 million and $0.6 million in expense related to the ESPP for the nine months ended September 30, 2020 and 2019, respectively. As of September 30, 2020, 202,102 shares were available under the ESPP for future issuance.
22

SEASPINE HOLDINGS CORPORATION
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)
The Company estimates the fair value of shares issued to employees under the ESPP using the Black-Scholes-Merton option-pricing model. The following weighted average assumptions were used in the calculation of fair value of shares under the ESPP at the grant date for the periods indicated:
Three Months Ended September 30,Nine Months Ended September 30,
2020201920202019
Expected dividend yield % % % %
Risk-free interest rate0.2 %1.9 %0.7 %1.4 %
Expected volatility 65.2 %36.6 %24.7 %21.9 %
Expected term (in years)1.31.30.80.7
10. LEASES
The impact of the adoption of Topic 842 to the Company's applicable balance sheet items as of January 1, 2020 is presented in the table below. The standard did not have a material impact to the Company's unaudited condensed consolidated statements of operations or comprehensive loss or cash flows.
(in thousands)December 31, 2019Impact of Adoption of ASC 842January 1, 2020
ASSETS
Right of use assets$ $9,059 $9,059 
Total assets$141,718 $9,059 $150,777 
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Other accrued expenses and current liabilities5,444 (138)5,306 
Current portion of operating lease liabilities 2,080 2,080 
  Total current liabilities30,478 1,942 32,420 
Operating lease liabilities, net of current portion 8,367 8,367 
Other liabilities1,480